SIGA Technologies Inc logo

SIGA - SIGA Technologies Inc News Story

$7.47 -0.1  -1.4%

Last Trade - 21/04/21

Mid Cap
Market Cap £411.6m
Enterprise Value £327.0m
Revenue £89.7m
Position in Universe 3372nd / 6852

SIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results

Fri 26th February, 2021 12:30pm
For best results when printing this announcement, please click on link below:

NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA)
(NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the
health security market, today announced that management will host a webcast
and conference call to provide a business update at 4:30 P.M. ET on Thursday,
March 4, 2021. Participating on the call will be Dr. Phil Gomez, Chief
Executive Officer, Daniel Luckshire, Chief Financial Officer, and Dr. Dennis
Hruby, Chief Scientific Officer.

A live webcast of the call will be available on the Company's website at under the 'Events & Presentations' tab in the Investor Relations
section, or by clicking here
Participants may also access the call by dialing 877-407-6184 for domestic
callers or 201-389-0877 for international callers. Please log in approximately
5-10 minutes prior to the scheduled start time.

A replay of the call will be available for two weeks by dialing 877-660-6853
for domestic callers or 201-612-7415 for international callers and using
Conference ID: 13715918. The archived webcast will be available in the Events
and Presentations section of the company's website


SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused
on the health security market. Health security comprises countermeasures for
biological, chemical, radiological and nuclear attacks (biodefense market),
vaccines and therapies for emerging infectious diseases, and health
preparedness. Our lead product is TPOXX®, also known as tecovirimat and
ST-246®, an orally administered and IV formulation antiviral drug for the
treatment of human smallpox disease caused by variola virus. TPOXX is a novel
small-molecule drug and the US maintains a stockpile of 1.7 million oral
courses in the Strategic National Stockpile under Project BioShield. The oral
formulation of TPOXX was approved by the FDA for the treatment of smallpox on
July 13, 2018. In September 2018, SIGA signed a contract with Biomedical
Advanced Research and Development Authority (BARDA) for additional procurement
and development related to both oral and intravenous formulations of TPOXX.
For more information about SIGA, please visit

About Smallpox(1)

Smallpox is a contagious, disfiguring and often deadly disease that has
affected humans for thousands of years. Naturally occurring smallpox was
eradicated worldwide by 1980, the result of an unprecedented global
immunization campaign. Samples of smallpox virus have been kept for research
purposes. This has led to concerns that smallpox could someday be used as a
biological warfare agent. A vaccine can prevent smallpox, but the risk of the
current vaccine's side effects is too high to justify routine vaccination for
people at low risk of exposure to the smallpox virus.


This press release contains certain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995, as amended.
Such forward-looking statements are subject to various known and unknown risks
and uncertainties, and SIGA cautions you that any forward-looking
information provided by or on behalf of SIGA is not a guarantee of future
performance. More detailed information about SIGA and risk factors that may
affect the realization of forward-looking statements, including the
forward-looking statements in this press release, is set forth
in SIGA's filings with the Securities and Exchange Commission,
including SIGA's Annual Report on Form 10-K for the fiscal year
ended December 31, 2020, and in other documents that SIGA has filed with
the SEC. SIGA urges investors and security holders to read those documents
free of charge at the SEC's web site at Interested
parties may also obtain those documents free of charge from SIGA.
Forward-looking statements are current only as of the date on which such
statements were made, and except for our ongoing obligations
under the United States of America federal securities laws, we undertake
no obligation to update publicly any forward-looking statements whether as a
result of new information, future events, or otherwise.

The information contained in this press release does not necessarily reflect
the position or the policy of the Government and no official endorsement
should be inferred.


Daniel J. Luckshire 


GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.